Health Care [ 7/12 ] | Biotechnology [ 36/76 ]
NASDAQ | Common Stock
ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies.
The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies.
It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection.
In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development.
Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes.
Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services.
The company is headquartered in Victoria, Canada.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Jul 29, 24 | -0.11 Increased by +47.62% | -0.11 |
Mar 14, 24 | -0.11 Increased by +42.11% | -0.10 Decreased by -10.00% |
Dec 14, 23 | -0.10 Increased by +66.67% | -0.13 Increased by +23.08% |
Sep 14, 23 | -0.14 Increased by +63.16% | -0.20 Increased by +30.00% |
Jul 7, 23 | -0.21 Increased by +4.55% | -0.17 Decreased by -23.53% |
Mar 16, 23 | -0.19 Increased by +5.00% | -0.23 Increased by +17.39% |
Dec 15, 22 | -0.30 Decreased by -15.38% | -0.19 Decreased by -57.89% |
Sep 14, 22 | -0.38 Decreased by -177.98% | -0.17 Decreased by -123.53% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Jul 31, 24 | 5.26 M Increased by +12.24% | -4.00 M Increased by +57.37% | Decreased by -75.98% Increased by +62.02% |
Apr 30, 24 | 6.46 M Increased by +14.91% | -18.05 M Decreased by -251.82% | Decreased by -279.38% Decreased by -206.18% |
Jan 31, 24 | 6.15 M Increased by +18.93% | -2.62 M Increased by +44.20% | Decreased by -42.63% Increased by +53.08% |
Oct 31, 23 | 6.15 M Increased by +18.63% | -2.62 M Increased by +64.33% | Decreased by -42.63% Increased by +69.93% |
Jul 31, 23 | 4.69 M Increased by 0.00% | -9.38 M Increased by 0.00% | Decreased by -200.06% Increased by 0.00% |
Apr 30, 23 | 5.62 M Increased by +7.29% | -5.13 M Decreased by -10.44% | Decreased by -91.25% Decreased by -2.94% |
Jan 31, 23 | 5.17 M Increased by +7.39% | -4.70 M Decreased by -22.82% | Decreased by -90.87% Decreased by -14.36% |
Oct 31, 22 | 5.18 M Increased by +9.78% | -7.35 M Decreased by -46.76% | Decreased by -141.80% Decreased by -33.68% |